On Friday 25 August, the European Commission announced that it had authorised Abrysvo, the first vaccine designed to protect the elderly and infants up to the age of six months against lower respiratory tract diseases caused by the respiratory syncytial virus (RSV).
This type of vaccine is particularly important given the rise in RSV infections in the EU last winter. The vaccine, which is now authorised throughout the EU, will help to boost the immune response to the virus. Considering...